According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The company’s product candidate consists of AZP-531 and ATR-101 which are in clinical stage. Millendo Therapeutics Inc., formerly known as OvaScience Inc., is based in Ann Arbor, United States. “
A number of other equities analysts have also issued reports on the company. Wedbush restated a buy rating and issued a $24.00 target price on shares of Millendo Therapeutics in a research note on Thursday, August 15th. Oppenheimer reduced their target price on Millendo Therapeutics from $26.00 to $25.00 and set an outperform rating for the company in a research note on Tuesday, August 13th. Citigroup started coverage on Millendo Therapeutics in a research note on Monday, July 15th. They issued an outperform rating and a $26.00 target price for the company. Jefferies Financial Group restated a buy rating and issued a $22.00 target price on shares of Millendo Therapeutics in a research note on Monday, September 16th. Finally, CIBC initiated coverage on Millendo Therapeutics in a research note on Tuesday, July 16th. They set an outperform rating and a $26.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $23.00.
Millendo Therapeutics (NASDAQ:MLND) last issued its earnings results on Monday, August 12th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.07. On average, sell-side analysts anticipate that Millendo Therapeutics will post -3.19 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Strs Ohio purchased a new position in shares of Millendo Therapeutics during the 2nd quarter valued at about $28,000. JPMorgan Chase & Co. grew its position in shares of Millendo Therapeutics by 285.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,580 shares of the company’s stock valued at $29,000 after acquiring an additional 1,911 shares during the period. Cubist Systematic Strategies LLC grew its position in shares of Millendo Therapeutics by 270.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,593 shares of the company’s stock valued at $30,000 after acquiring an additional 1,893 shares during the period. Wells Fargo & Company MN grew its position in shares of Millendo Therapeutics by 1,830.5% during the 2nd quarter. Wells Fargo & Company MN now owns 14,479 shares of the company’s stock valued at $168,000 after acquiring an additional 13,729 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Millendo Therapeutics during the 2nd quarter valued at about $208,000. Institutional investors and hedge funds own 50.47% of the company’s stock.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Featured Article: Market Capitalization
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.